Dr. Andrew Miller
President, CEO, Board Member, and Co-founder

Dr. Miller is the President and Chief Executive Officer of Karuna Pharmaceuticals. Dr. Miller co-founded Karuna as part of his role at PureTech Health, and is the lead inventor of Karuna’s KarXT platform. Dr. Miller also serves as a member of the Board of Directors of Karuna and Entrega. In 2016, Dr. Miller was named one of the top 40 innovators under 40 by MedTech Boston. He completed his doctoral work in Chemical Engineering at the Massachusetts Institute of Technology and received the MIT Presidential fellow and National Defense Science and Engineering Graduate fellowship awards. Dr. Miller received a B.S. in Chemical Engineering from the University of Illinois with highest honors.

Dr. Ben Shapiro  
Board Member

Dr. Shapiro is a Non-Executive Director. He was previously Executive Vice President of Research for Merck. In this position he was responsible for all basic and preclinical research activities at Merck worldwide. Dr. Shapiro led the research program that resulted in FDA registration of approximately 25 drugs and vaccines. In addition to overseeing Merck internal research, Shapiro was responsible for in-licensing activities. Previously, he was Professor and Chairman of the Department of Biochemistry at the University of Washington.

He is the author of over 120 papers on the molecular regulation of cellular behavior and the biochemical events that integrate the cascade of cellular activations at fertilization. He has served on many institutional advisory boards and scientific review panels, and has been a member of the board of various life science companies, including Momenta, Celera and Ikaria. He also sits on the boards of PureTech Health, the Drugs for Neglected Disease Initiative and the Mind and Life Institute. Dr. Shapiro received his MD from Jefferson Medical College.

Dr. Edmund Harrigan
Board Member

Dr. Harrigan is a Non-Executive Director.  He previously served as Senior Vice President of Worldwide Safety and Regulatory for Pfizer Inc. from 2012 to 2015, where he led a 3,500-person team in 80 countries that was responsible for collecting, interpreting and reporting clinical safety data for more than 600 marketed products, and managed regulatory interactions with global health agencies. Dr. Harrigan’s previous executive leadership roles at Pfizer include serving as Senior Vice President, Head of Worldwide Business Development, Senior Vice President, Head of Worldwide Regulatory Affairs and Quality Assurance, and Vice President, Head of Neuroscience and Ophthalmology. Earlier in his career at Pfizer, Dr. Harrigan served as Vice President of Clinical Development, Therapeutic Area Head, CNS and Pain. Before entering the pharmaceutical industry in 1990, Dr. Harrigan was a practicing neurologist for seven years. He currently serves on the Board of Directors of Acadia Pharmaceuticals, Inc. Dr. Harrigan earned his B.A. degree in Chemistry from St. Anselm College and holds an M.D. from the University of Massachusetts at Worcester. He also attended the Brain Research Institute at the University of California, Los Angeles.


Dr. Atul Pande
Board Member

Dr. Pande is a Non-Executive Director.  He has more than 25 years of experience in the fields of psychiatry and neurosciences and an expertise in drug development. Dr. Pande is the former Senior Vice President, Head of Neuroscience, and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline.  Dr. Pande has been active in the development of multiple important central nervous system drugs while holding various senior roles in Pfizer R&D, ParkeDavis/Warner-Lambert, and Lilly Research Laboratories. His experience includes drug development, registration, launch and lifecycle management in the areas of anxiety, depression, epilepsy, neuropathic pain, schizophrenia, traumatic brain injury, and Alzheimer's and Parkinson's diseases. Dr. Pande is a psychiatrist and fellow of several scientific societies, including the American Psychiatric Association. Dr. Pande currently serves as Chief Medical Officer and Scientific Advisory Board member at Tal Medical; Senior Advisor to PureTech Health; on the Board of Directors of Axovant Sciences and Autifony Therapeutics; on the Scientific Advisory Board of Cennerv Pharma; and as President of Verity BioConsulting. He began his career as a faculty member at the University of Michigan Medical School where his research focused on mood disorders. He has published over 50 peer-reviewed scientific papers and over 100 abstracts, book chapters, and book reviews.

Dr. Eric Elenko,
Co-Founder and Board Member

Dr. Elenko is a Non-Executive Director.  Dr. Elenko is the Chief of Research and Strategy at PureTech Health where he has led the development of a number of programs, including Akili Interactive Labs, Gelesis, Karuna Pharmaceuticals and Sonde Health. Previously, Dr. Elenko was a consultant with McKinsey and Company where he advised senior executives of both Fortune 500 and specialty pharmaceutical companies on a range of issues such as product licensing, mergers and acquisitions, research and development strategy and marketing. Dr. Elenko received his BA in Biology from Swarthmore College and his PhD in Biomedical Sciences from University of California, San Diego.

Mr. Stephen Muniz
Board Member

Stephen Muniz, JD, is a Non-Executive director.  Mr. Muniz the Chief Operating Officer and a member of PureTech Health’s Board of Directors. Previously, Mr. Muniz was a Partner in the Corporate Department of Locke Lord LLP, where he practiced law for 10 years. Mr. Muniz’s practice at Locke Lord LLP focused on the representation of life science venture funds as well as their portfolio companies in general corporate matters and in investment and liquidity transactions.


Prior to joining Locke Lord LLP, Mr. Muniz was a law clerk to Hon. Raya Dreben at the Massachusetts Appeals Court. He was also a Kauffman Entrepreneur Fellow, a programme sponsored by the Kauffman Foundation. Mr. Muniz also sits on the board of directors of Karuna, Entrega, Follica and Gelesis. Mr. Muniz has a BA in Economics and Accounting from The College of the Holy Cross and a JD from the New England School of Law where he graduated summa cum laude. Mr. Muniz was Valedictorian of the 1997 New England School of Law Commencement and has been awarded the Amos L. Taylor Award for Excellence in Scholarship, the New England Scholar Award and the NESL Trustee Scholar Award.


Dr. Brannan is a neuroscience drug development expert who has held senior positions overseeing both clinical development and medical affairs with more than 15 years of industry experience.  Previously, Dr. Brannan was the Therapeutic Head of Neuroscience at Takeda and Vice President for Clinical Research and Medical Affairs at Forum Pharmaceuticals. Dr. Brannan has been active in the development of multiple important central nervous system treatments including Cymbalta, Exelon Patch, Trintellix, and VNS for Treatment Resistant Depression while holding various senior roles at Forum, Takeda, Novartis, Cyberonics, and Eli Lilly. His experience includes drug development, registration, medical affairs, launch and lifecycle management across psychiatry and neurology.  Dr. Brannan is a board certified and is a member of several scientific societies and groups, including ISCTM, ISCDD, AARR, IOM Neuroforum, and CNS Summit (founding member). Prior to joining the Pharmaceutical industry, Dr. Brannan worked on the faculty at the University of Texas Health Science Center at San Antonio (UTHSCSA) where he specialized in seeing Mood and Anxiety disorder patients, ran a clinical research unit, and did neuroimaging research at the Research Imaging Center.  Dr. Brannan trained in psychiatry at UTHSCSA and holds a M.D. degree from the University of Texas Health Science Center at Dallas (Southwestern Medical School). He has over 40 publications and routinely gives invited talks and presentation at industry conferences.

Dr. Alan Breier
Chief Clinical Advisor

Dr. Alan Breier is Karuna’s Chief Clinical Advisor. Dr. Breier previously was the Chief Medical Officer at Eli Lilly and is currently Professor of Psychiatry and Vice Chair for Clinical Research at Indiana University School of Medicine and Chief of the Psychotic Disorders Program. He is also the Director of Research at Larue Carter Hospital.  He was a member of Lilly Research Laboratories’ policy committee and the company’s senior management council. Previously, Dr. Breier was a clinical research fellow at Eli Lilly, product team leader for the antipsychotic drug Zyprexa and Vice President of Pharmaceutical Products at Eli Lilly. Prior to joining Eli Lilly, Dr. Breier was Chief of the section of clinical studies at the NIMH Intramural Research Program and prior to that the Chief of the outpatient research program at the Maryland Psychiatric Research Center. He has published over 250 scientific articles and is the recipient of several awards.